DiaSorin (OTCMKTS:DSRLF) Trading Down 17.4% - Time to Sell?

Key Points

• DiaSorin fell 17.4% intraday to $67.00 from a prior close of $81.15, with only 10 shares traded—about a 92% drop from its average session volume—indicating a sharp move on extremely low liquidity.
• Analyst coverage is mixed: two Buy and two Hold ratings leave the stock with an average rating of "Moderate Buy" from MarketBeat's data.
• The share price sits well below its technical benchmarks (50-day SMA ~$82.15 and 200-day SMA ~$82.78); DiaSorin is an Italy-based diagnostics company specializing in immunodiagnostic and molecular tests.

DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) traded down 17.4% on Monday . The stock traded as low as $67.00 and last traded at $67.00. 10 shares traded hands during trading, a decline of 92% from the average session volume of 125 shares. The stock had previously closed at $81.15.

Wall Street Analyst Weigh In

DSRLF has been the subject of a number of research analyst reports. BNP Paribas Exane raised DiaSorin to a "neutral" rating in a report on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of DiaSorin in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy".

DiaSorin Stock Down 17.4%

The stock has a 50 day simple moving average of $82.15 and a two-hundred day simple moving average of $82.78.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company's shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin's business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.